Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Net Income towards Common Stockholders (2016 - 2026)

Lexaria Bioscience's Net Income towards Common Stockholders history spans 12 years, with the latest figure at $1.4 million for Q1 2026.

  • Quarterly results put Net Income towards Common Stockholders at $1.4 million for Q1 2026, down 48.15% from a year ago — trailing twelve months through Feb 2026 was $9.5 million (up 1.06% YoY), and the annual figure for FY2025 was $11.9 million, up 105.17%.
  • Net Income towards Common Stockholders for Q1 2026 was $1.4 million at Lexaria Bioscience, down from $1.6 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $3.8 million in Q2 2025 to a low of -$2.4 million in Q2 2022.
  • The 5-year median for Net Income towards Common Stockholders is $1.6 million (2025), against an average of $1.5 million.
  • The sharpest move saw Net Income towards Common Stockholders soared 452.82% in 2022, then plummeted 53.85% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at $1.8 million in 2022, then plummeted by 33.33% to $1.2 million in 2023, then skyrocketed by 125.0% to $2.7 million in 2024, then plummeted by 40.74% to $1.6 million in 2025, then decreased by 12.5% to $1.4 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at $1.4 million, $1.6 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.